5 research outputs found
Additional file 1: Figure S1. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis
Mean concentration–time profiles of lapachol after (A) 2 mg/kg i.v., (B) 10 mg/kg oral, and (C) 25 mg/kg oral administration to rats. Data points are mean ± standard deviation. (PDF 146 kb
Additional file 2: TableS1. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis
LAP and LAP sodium salt pharmacokinetic parameters determined by noncompartmental and compartmental approaches after i.v. administration of 2Â mg/kg in Wistar rats. (PDF 93Â kb
Additional file 6: Figure S3. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis
Serum levels of GPT and AST in LAP-treated mice during CIA protocol. (PDF 518Â kb
Additional file 5: Table S3. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis
Evaluation of the toxicity of lapachol in proliferating CD4 T cells. (PDF 224Â kb
Additional file 4: Figure S2. of Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis
Superimposition of the crystallographic hDHODH inhibitor A771726 (PDB id:1D3H, carbon atoms in cyan) and the top-ranked docking solution (carbon atoms in yellow), inside the active site. (PDF 458Â kb